JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265912

Human HAGH (GLO2) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

HAGH KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 4 bp deletion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human HAGH (GLO2) knockout HeLa cell line (AB265912)
  • Sanger seq

Unknown

Sanger Sequencing - Human HAGH (GLO2) knockout HeLa cell line (AB265912)

Allele-1 : 16 bp deletion in exon 3.

Sanger Sequencing - Human HAGH (GLO2) knockout HeLa cell line (AB265912)
  • Sanger seq

Unknown

Sanger Sequencing - Human HAGH (GLO2) knockout HeLa cell line (AB265912)

Allele-2 : 4 bp deletion in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 4 bp deletion in exon 3

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265912-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265912 Human HAGH (GLO2) knockout HeLa cell line", "number":"AB265912-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265912-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265912-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265912-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265912 Human HAGH (GLO2) knockout HeLa cell line", "number":"AB265912-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265912-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265912 Human HAGH (GLO2) knockout HeLa cell line", "number":"AB265912-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265912-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265912 Human HAGH (GLO2) knockout HeLa cell line", "number":"AB265912-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
HAGH
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glyoxalase 2 also known as GLO2 is an important enzyme in the glyoxalase system. The protein's molecular mass is approximately 29 kDa. It catalyzes the conversion of S-D-lactoylglutathione to glutathione and D-lactic acid allowing the detoxification of methylglyoxal a byproduct of glycolysis. GLO2 is expressed in many tissues with higher levels in liver and kidney reflecting its importance in detoxifying processes.
Biological function summary

Glyoxalase 2 has a significant role in cellular detoxification and maintenance of redox balance. As part of the glyoxalase system it closely works with another enzyme glyoxalase 1 to detoxify methylglyoxal. Through this interaction GLO2 helps prevent harmful effects caused by excessive levels of advanced glycation end-products (AGEs) protecting cells from potential damage.

Pathways

Glyoxalase 2 is involved in the methylglyoxal degradation pathway within the cellular glucose metabolism process. Specifically it partners with glyoxalase 1 in this detoxification route. Additionally GLO2 contributes to glutathione metabolism where it plays a critical part alongside glutathione peroxidases which further regulate oxidative stress.

GLO2 is associated with diabetes and neurodegenerative diseases. Altered levels of glyoxalase 2 impact methylglyoxal levels and have implications in diabetic complications through protein glycation. Furthermore studies indicate its potential link with Alzheimer's disease where oxidative stress and AGEs accumulation play central roles. GLO2's connection with glyoxalase 1 remains significant as both participate in these pathological states.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com